Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.30 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25671082 | 1.00 | TDP1 (0.36) | TDP1MEN1KMT2AGAACAPN1 | |
| SCHEMBL26081443 | 0.92 | TDP1 (0.32) | TDP1MEN1KMT2AGAACAPN1 | |
| SCHEMBL21104000 | 0.92 | CAPN1 (0.33) | TDP1MEN1KMT2AGAACAPN1 | |
| SCHEMBL26229088 | 0.90 | TDP1 (0.32) | TDP1MEN1KMT2AGAACAPN1 | |
| SCHEMBL21103703 | 0.90 | TDP1 (0.32) | TDP1MEN1KMT2AGAACAPN1 | |
| SCHEMBL25671162 | 0.81 | TDP1 (0.40) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL25671080 | 0.81 | TDP1 (0.40) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL18501604 | 0.77 | MAPK1 (0.34) | TDP1 | |
| SCHEMBL26229150 | 0.75 | GRN (0.38) | CAPN1CTSSCTSK | |
| SCHEMBL18506522 | 0.72 | SIRT6 (0.35) | CA1CA2SIRT6SIRT1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067967-A1 | OPTIMIZED ANTI-FLT1 OLIGONUCLEOTIDE COMPOUNDS FOR TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS | UNIV MASSACHUSETTS (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230399645-A1 | OPTIMIZED SIRNA SCAFFOLDS | UNIVERSITY OF MASSACHUSETTS | 2023-12-14 | — | — | US | disclosed |
| US-20230348907-A1 | OLIGONUCLEOTIDES FOR MECP2 MODULATION | UNIVERSITY OF MASSACHUSETTS | 2023-11-02 | — | — | US | disclosed |
| US-20230340475-A1 | OLIGONUCLEOTIDES FOR MLH1 MODULATION | UNIV MASSACHUSETTS (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230313198-A1 | OLIGONUCLEOTIDES FOR MLH3 MODULATION | UNIV MASSACHUSETTS (US) | 2023-10-05 | — | — | US | disclosed |
| US-11753638-B2 | Conjugated oligonucleotides | UNIVERSITY OF MASSACHUSETTS (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753638-B2 | Conjugated oligonucleotides | UNIVERSITY OF MASSACHUSETTS (US) | 2023-09-12 | — | — | US | disclosed |
| US-11702659-B2 | Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders | UNIVERSITY OF MASSACHUSETTS (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230193281-A1 | OLIGONUCLEOTIDES FOR SOD1 MODULATION | UNIVERSITY OF MASSACHUSETTS | 2023-06-22 | — | — | US | disclosed |
| US-20190185855-A1 | CONJUGATED OLIGONUCLEOTIDES | UNIVERSITY OF MASSACHUSETTS | 2019-06-20 | — | — | US | disclosed |
| US-20170043024-A1 | BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY | UNIVERSITY OF MASSACHUSETTS | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340475-A1 | OLIGONUCLEOTIDES FOR MLH1 MODULATION | MSH2, MSH6, PMS2 | TDP1 30/4885MEN1 646/4885KMT2A 477/4885 |
| US-11702659-B2 | Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders | FLT1, FLT4, TEK | TDP1 108/4885MEN1 2639/4885KMT2A 2211/4885 |
| US-20240067967-A1 | OPTIMIZED ANTI-FLT1 OLIGONUCLEOTIDE COMPOUNDS FOR TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS | FLT1, FLT4, TEK | TDP1 108/4885MEN1 2639/4885KMT2A 2211/4885 |
| US-11753638-B2 | Conjugated oligonucleotides | DCLRE1B, DCLRE1A, TNNC1 | TDP1 400/4885MEN1 3721/4885KMT2A 3423/4885 |
| US-20230193281-A1 | OLIGONUCLEOTIDES FOR SOD1 MODULATION | SOD1, SOD3, SMN1; SMN2 | TDP1 63/4885MEN1 4841/4885KMT2A 3419/4885 |
| US-20170043024-A1 | BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY | DCLRE1B, RTCB, RNASE1 | TDP1 718/4885MEN1 3137/4885KMT2A 4018/4885 |
| US-20190185855-A1 | CONJUGATED OLIGONUCLEOTIDES | DCLRE1B, DCLRE1A, TNNC1 | TDP1 400/4885MEN1 3721/4885KMT2A 3423/4885 |
| US-20230348907-A1 | OLIGONUCLEOTIDES FOR MECP2 MODULATION | MECP2, TARDBP, SMN1; SMN2 | TDP1 70/4885MEN1 4158/4885KMT2A 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.